Sign in to view content

ENVISION Trial 24-Week Data: Phase 2 Study of UBX1325, a New Senolytic Agent for Patients With Wet AMD

Raj K. Maturi, MD

Video
Published 2023

Related

Does Anti-VEGF Therapy Affect the Rate of Expansion of Geographic Atrophy in Patients with Neovascular AMD Managed by a Treat-Extend-Stop Protocol?
Sean David Adrean, MD, FAAO, FASRS
On Demand Cases, Courses, and Papers
2019
Exudative Macular Degeneration
Pamela Rowlett
Retina Image Bank: Images of the Week
Episode 15: Serum VEGF Levels in the IVAN Trial with Dr. Usha Chakravarthy
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018

Category: AMD-Neovascular

See more